Ma, Xiaosu

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 478

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study

Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 184

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

Ray, K. K., Oru, E., Rosenson, R. S., Jones, J., Ma, X., Walgren, J., Haupt, A., Verma, S., Gaudet, D., Nicholls, S. J., et al. (2025) · The Lancet

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 81

Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants

Pratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 62

Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes

Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 60

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist

Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024) · Diabetes Therapy

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 38

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight

Ma, X., Li, Y. G., Raha, S., Sperry, D. C., Coutant, D. E., & Bhattachar, S. (2026) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 13

Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants

Morse, B. L., Bhattachar, S., Ma, X., Coutant, D. E., Czeskis, B., Nicoll, C., & Cassidy, K. C. (2026) · Clinical Pharmacology in Drug Development

Diabetes Treatment and ManagementPharmacogenetics and Drug Metabolism

Cited by 7